These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 31616384)

  • 1. Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease.
    Jiang M; Li C; Liu Q; Wang A; Lei M
    Front Endocrinol (Lausanne); 2019; 10():665. PubMed ID: 31616384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
    Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
    Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
    Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
    Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis.
    Kasumov T; Li L; Li M; Gulshan K; Kirwan JP; Liu X; Previs S; Willard B; Smith JD; McCullough A
    PLoS One; 2015; 10(5):e0126910. PubMed ID: 25993337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice.
    Presa N; Clugston RD; Lingrell S; Kelly SE; Merrill AH; Jana S; Kassiri Z; Gómez-Muñoz A; Vance DE; Jacobs RL; van der Veen JN
    Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):14-25. PubMed ID: 30300671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis.
    Martínez L; Torres S; Baulies A; Alarcón-Vila C; Elena M; Fabriàs G; Casas J; Caballeria J; Fernandez-Checa JC; García-Ruiz C
    Oncotarget; 2015 Dec; 6(39):41479-96. PubMed ID: 26539645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
    Régnier M; Polizzi A; Guillou H; Loiseau N
    Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease.
    Li DJ; Liu J; Hua X; Fu H; Huang F; Fei YB; Lu WJ; Shen FM; Wang P
    Metabolism; 2018 Feb; 79():52-63. PubMed ID: 29129819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives.
    Yu XD; Wang JW
    Biochem Pharmacol; 2022 Aug; 202():115157. PubMed ID: 35777449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of constant light exposure on sphingolipidomics and progression of NASH in high-fat-fed rats.
    Yue F; Xia K; Wei L; Xing L; Wu S; Shi Y; Lam SM; Shui G; Xiang X; Russell R; Zhang D
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1978-1989. PubMed ID: 32027419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
    Zhuge B; Li G
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
    Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydrosphingolipids are associated with steatosis and increased fibrosis damage in non-alcoholic fatty liver disease.
    Babiy B; Ramos-Molina B; Ocaña L; Sacristán S; Burgos-Santamaría D; Martínez-Botas J; Busto R; Perna C; Frutos MD; Albillos A; Pastor Ó
    Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Jul; 1868(7):159318. PubMed ID: 37059386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of exercise on high-fat diet-induced non-alcoholic fatty liver disease and lipid metabolism in ApoE knockout mice.
    Huang WC; Xu JW; Li S; Ng XE; Tung YT
    Nutr Metab (Lond); 2022 Feb; 19(1):10. PubMed ID: 35172845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of Ceramides in Non-Alcoholic Fatty Liver Disease.
    Hajduch E; Lachkar F; Ferré P; Foufelle F
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.